European Commission approves Roche’s Tecentriq as adjuvant treatment for early-stage NSCLC
The approval marks Tecentriq’s sixth lung cancer indication in Europe
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.